共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Stem cell therapy holds the promise to treat degenerative diseases, cancer and repair of damaged tissues for which there are
currently no or limited therapeutic options. The potential of stem cell therapies has long been recognised and the creation
of induced pluripotent stem cells (iPSC) has boosted the stem cell field leading to increasing development and scientific
knowledge. Despite the clinical potential of stem cell based medicinal products there are also potential and unanticipated
risks. These risks deserve a thorough discussion within the perspective of current scientific knowledge and experience. Evaluation
of potential risks should be a prerequisite step before clinical use of stem cell based medicinal products. 相似文献
14.
15.
16.
17.
18.
Cirrhosis is a chronic condition that can lead to liver failure. Currently, the viable option for decreasing mortality is liver transplantation. However, transplant surgery is highly invasive. Therefore, cell-based therapy has been developed as an alternative. Based on promising findings from preclinical research, some new trials have been registered. One of them was autologous bone marrow cell infusion therapy and found that ameliorating liver fibrosis activated liver regeneration. Now, majority of trials focus on low-immunogenicity mesenchymal stem cells (MSCs) appropriate for allogeneic administration. However, despite about 20 years of research, only a limited number of cell-based therapies have entered routine practice. Furthermore, potential shortcomings of cell-based therapy include a limit on the number of cells, which may be administered, as well as their failure to infiltrate target organs. On the other hand, these research show that MSCs act as “conducting cells” and regulate host cells including macrophages via extracellular vesicles (EVs) or exosome signals, leading to ameliorate liver fibrosis and promote regeneration. Therefore, the concept of cell-free therapy, which makes use of cell-derived EVs or exosomes, is attracting attention. Cell-free therapies may be safely administered in large doses and are able to infiltrate target organs. However, development of cell-free therapy exhibits its own set of challenges and such therapy may not be completely curative in the context of liver disease. This review describes the history of cell-based therapy research and recent advances in cell-free therapy, as well as discussing the need for more effective therapies. 相似文献